Bioactive Research Peptides
GHRH-T44
Available
Volume savings
Automatic discounts across eligible products and sizes.
- 2+ items5% off
- 3+ items10% off
- 5+ items15% off
- 10+ items20% off
Savings apply automatically in your cart.
Offer details
Mix eligible products and sizes, including Retatrutide vials. Items already in your cart count toward your discount. View cart.
SKU: GHRH-T44-10MG
Supplied for laboratory research and development. Not for human or veterinary use, consumption, or clinical applications.
Product information
About GHRH-T44
GHRH-T44 Research Peptide
GHRH-T44 is offered as a laboratory research peptide. Confirm the full product identity and presentation for your project; this listing should not be treated as interchangeable with the shorter GHRH(1-29) material commonly called sermorelin.
Product information
Select from the presentations shown on this page. For a specific batch or analytical requirement, contact [email protected] for available product documentation before ordering.
Read the GHRH-T44 research guide
For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, or clinical application.
Product research information
GHRH-T44 is a synthetic growth hormone-releasing hormone analog with the molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S. It is structurally based on the full 44-amino-acid human growth hormone-releasing factor sequence and includes an N-terminal trans-3-hexenoyl modification. This modification has been studied for its ability to improve peptide stability by reducing susceptibility to enzymatic degradation, including degradation associated with dipeptidyl peptidase-IV (DPP-IV).
Research involving GHRH-T44 focuses on its interaction with growth hormone-releasing hormone receptors located on somatotroph cells of the anterior pituitary. In laboratory models, receptor binding has been associated with stimulation of endogenous growth hormone signaling and downstream evaluation of insulin-like growth factor 1 (IGF-1) response. Because this compound acts through the GHRH receptor pathway, it is commonly studied in relation to pulsatile growth hormone release patterns rather than direct growth hormone replacement.
A major area of investigation involves metabolic signaling, lipid metabolism, and body-composition-related research models. Studies have evaluated GHRH analogs for their effects on visceral adipose tissue, hepatic lipid markers, triglyceride regulation, and broader metabolic dysregulation pathways. These research applications make GHRH-T44 useful for studying the relationship between growth hormone axis modulation, lipolysis, and adipose tissue distribution in controlled non-clinical settings.
References
Ferdinandi, E. S., et al. (2007). “Preclinical pharmacokinetics and metabolism of TH9507, a growth hormone-releasing factor analog, in mice, rats, dogs, and monkeys.” Journal of Endocrinology, 195(1), 1-14.
Makimura, H., et al. (2013). “Reduced growth hormone secretion is associated with increased visceral adiposity in healthy older adults.” The Journal of Clinical Endocrinology & Metabolism, 98(5), 2090-2097.
Stanley, T. L., et al. (2011). “Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.” The Journal of Clinical Endocrinology & Metabolism, 96(1), 150-158.
Need help with product information?
Our team can help with available formats, bulk quantities, and documentation requests.